Skip to main content
Clinical Trials/NCT06212908
NCT06212908
Completed
N/A

Integrating Periodontal Therapy and Biofilm Management Into Breast Cancer Patients' Care: Periodontal, Hematological and Salivary Parameters Assessment Before and During Chemotherapy

University of Sao Paulo0 sites40 target enrollmentSeptember 18, 2012

Overview

Phase
N/A
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
University of Sao Paulo
Enrollment
40
Primary Endpoint
Periodontal conditions
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Objective: To evaluate the impact of chemotherapy on periodontal conditions, hematology, and salivary flow in patients with breast cancer and gingivitis, after basic periodontal therapy (BPT).

Methods: They were divided into patients with breast cancer and gingivitis (BC/G =20); and patients without cancer with gingivitis (G=20). Clinical parameters [Plaque Index (PI), bleeding on probing (BOP), Probing Depth (PS), Clinical Attachment Level (CAL)], hematological parameters (complete blood count), and salivary flow were evaluated at baseline, 6, 12 and 24 weeks.

Detailed Description

Objective: To evaluate the impact of chemotherapy on periodontal conditions, hematology, and salivary flow in patients with breast cancer and gingivitis, after basic periodontal therapy (BPT). Methods: They were divided into patients with breast cancer and gingivitis (BC/G =20); and patients without cancer with gingivitis (G=20). Clinical parameters \[Plaque Index (PI), bleeding on probing (BOP), Probing Depth (PS), Clinical Attachment Level (CAL)\], hematological parameters (complete blood count), and salivary flow were evaluated at baseline, 6, 12 and 24 weeks.

Registry
clinicaltrials.gov
Start Date
September 18, 2012
End Date
December 2016
Last Updated
2 years ago
Study Type
Interventional
Study Design
Sequential
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kelly Rocio Vargas Villafuerte

Principal Investigator

University of Sao Paulo

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • systemic diseases (e.g. diabetes, cardiovascular diseases) or autoimmune diseases in addition to cancer; 2) patients with periodontitis; 3) use of any medication that could interfere with periodontal aspects; 4) smokers; 5) Pregnant or lactating patients.

Outcomes

Primary Outcomes

Periodontal conditions

Time Frame: before and after post treatment (baseline, 6 weeks, 12 and 24 weeks)

The plaque index (PI) was determined by analyzing the presence or absence of biofilm on the gingival margin, expressed as a percentage of surfaces with biofilm Bleeding on probing (BOP) was determined by detecting the presence or absence of bleeding, expressed as the percentage of bleeding surfaces. The probing depth (PD/mm) was expressed in millimeters, measured from the gingival margin to the bottom of the gingival sulcus. The clinical attachment level (CAL/mm) was expressed in millimeters, measured from the cementoenamel junction to the most apical portion of the gingival sulcus. Both BOP, PD, CAL were evaluated at six locations per tooth, i.e., three on the buccal surface and three on the lingual or palatal surface. Periodontal parameters (BOP, PD, CAL and PI ) are evaluated together or combined to perform periodontal diagnosis

Secondary Outcomes

  • Salivary Flow(before and after post treatment (baseline, 6 weeks, 12 and 24 weeks))

Similar Trials